[{"id":"928e30bf-7cde-48fe-9006-0210ef5ddbda","acronym":"","url":"https://clinicaltrials.gov/study/NCT05885464","created_at":"2023-06-02T14:05:57.682Z","updated_at":"2024-07-02T16:34:59.472Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","source_id_and_acronym":"NCT05885464","lead_sponsor":"Beam Therapeutics Inc.","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BEAM-201"],"overall_status":"Recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 05/25/2023","start_date":" 05/25/2023","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-06-03"}]